Study: Unapproved copies of Lilly's obesity drug underperform
A new study indicates that patients using unapproved versions of Eli Lilly's retatrutide, a triple agonist, experience significantly less weight loss than those on the authentic drug. The authentic drug has shown up to 25% weight loss in Phase 3 trials, but gray-market alternatives appear to be less effective. The findings highlight risks associated with sourcing medications outside regulated channels.
The study compared outcomes between patients taking the regulated version of retatrutide and those who obtained the drug through unofficial channels. While the authentic medication produced substantial weight reduction in earlier clinical testing, the unapproved formulations yielded markedly diminished results. This discrepancy suggests that copycat products may lack the potency or consistency of the original.
The findings underscore a growing concern in the weight-loss drug market, where demand for effective treatments has outpaced supply. Patients seeking cheaper or more accessible alternatives may unknowingly receive products with unpredictable quality. Regulators and healthcare providers have long warned that medications purchased outside approved distribution networks carry unknown risks, including contamination, incorrect dosing, or inactive ingredients.
This study could affect patients who are considering gray-market options for weight-loss drugs, particularly those facing high costs or insurance barriers. It may also influence how physicians counsel patients about sourcing medications and could prompt regulators to strengthen enforcement against unauthorized sales. The findings reinforce the importance of clinical oversight in obesity treatment, as substandard alternatives might delay effective care or expose users to unforeseen health complications.